Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Docetaxel and Carboplatin for Treatment of Patients With Metastatic, Castration Resistant Prostate Cancer and Germline or Somatic DNA Repair Deficiency

NCT02985021 is registered in ClinicalTrials.gov with Seattle Institute for Biomedical and Clinical Research as lead sponsor.

NCT NCT02985021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02985021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Docetaxel and Carboplatin for Treatment of Patients With Metastatic, Castration Resistant Prostate Cancer and Germline or Somatic DNA Repair Deficiency
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Phase
Phase 2
Overall status
Terminated
Start date
November 30, 2016
Completion date
April 30, 2021
Enrollment
2 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hormone-resistant prostate cancer, metastatic prostate carcinoma, recurrent prostate carcinoma, stage iv prostate cancer